Kailera Therapeutics, Inc. 2Q 2026: Revenue N/A, Net loss $(111.3M), EPS $(1.09) — 10-Q Summary
KLRA
Kailera Therapeutics, Inc. reported results for the quarter ended 2Q 2026 showing no product or other revenue and a widened net loss. The company recorded a net loss attributable to common stockholders of $(111.3M) versus a net loss of $(28.9M) in the year‑ago quarter, with basic and diluted loss per share of $(1.09) for 2Q 2026
- Revenue: Not reported for the periods presented (no product or other revenue disclosed).
- Net income: Net loss attributable to common stockholders of $(111.3M) for 2Q 2026, compared with a net loss of $(28.9M) in the year‑ago quarter (YoY deterioration of $(82.4M)).
- Diluted EPS: Basic and diluted net loss per share attributable to common stockholders of $(1.09) for 2Q 2026 (prior-year figure not meaningful due to different share counts).
Business Highlights
- Pipeline progress: Advancing four clinical-stage GLP-1–based candidates, including global Phase 3 ribupatide injection trials and oral and tri-agonist programs.
- Clinical momentum: Partner Hengrui reported positive Phase 3 topline results in China for ribupatide and KAI-7535, showing strong HbA1c and weight-loss signals.
- R&D investment: The company significantly ramped R&D spending to support Phase 3 trials, manufacturing and program expansion, driving higher operating activity.
- Liquidity: Cash and marketable securities are expected to support operations into mid-2028, enabling continued trial progression and commercial preparations.
Original SEC Filing:Kailera Therapeutics, Inc. [ KLRA ] – 10-Q – Aug. 12, 2026
DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.
EarningsTradingViewUS stocks
